This study will examine the efficacy of intranasal oxytocin versus placebo in combination with Alcohol Behavioral Couples Therapy (ABCT) to reduce alcohol use disorder severity. We will also use observational coding and neuroimaging to examine behavioral and neural mechanisms underlying treatment outcomes.
The goal of this project is to conduct interviews with 50 Veterans in order to inform the development of a treatment protocol to reduce substance use disorder symptoms and relationship problems simultaneously. Group and individual interviews are expected to last approximately 60-90 minutes.
This Charleston Alcohol Research Center (ARC) pilot study seeks to provide the preliminary validation of a novel natural rewards fMRI paradigm which may be used in the development and/or evaluation of alcohol addiction medication treatments. Specifically, individuals with alcohol use disorder (AUD) and social drinkers will be recruited for a magnetic resonance imaging (MRI) study which will include magnetic resonance spectroscopy, an alcohol cue task, and this novel natural rewards paradigm which examines brain response to social reward and food. Invited participants will complete an initial screening diagnostic assessment visit at the Medical University of South Carolina, which will consist of clinical interviews with research staff, questionnaires, and labs. If still eligible, participants will be invited for a second appointment which will include additional clinical measures, questionnaires, and an MRI scan. This study is confidential and participants will be compensated for participating.
The proposed study will employ treatment-seeking AUD individuals who will be randomly assigned to receive either 15 mg of rapamycin (sirolimus) or placebo immediately after the first of two alcohol cue exposure sessions scheduled to occur on consecutive days. Subjective responses (i.e., craving) and physiological (heart rate & skin conductance) reactivity will be obtained before, during and after cue presentations in both sessions. The durability of any observed treatment effects will be assessed in a Follow-up session performed approximately 10 days following completion of the second session. Treatment effects on self-report measures of drinking behavior during the approximately 10 days preceding the Follow-up session will also be assessed.
The purpose of this study is to evaluate the potential mechanism of action and the safety of GET73, a new drug under development for the reduction of craving and drinking in alcohol dependent individuals. The study involves five to six visits over a three to four week period, including one to two assessment visits and two visits during which participants will be assigned to take, in a double-blinded fashion, both GET73 and a placebo (two visits during each condition). During three of these visits, participants will undergo a one-hour MRI scan. Compensation is available for qualified participants.
This study examines the effects of the medication gabapentin and the supplement n-acetylcysteine among individuals with Bipolar Disorder who regularly drink alcohol. Participants in this study will take gabapentin, n-acetylcysteine, and matched placebo (one at a time) for 5 days each. There are 8 study visits, including 3 MRI scans.
Individuals with anxiety disorders are approximately twice as likely as the general population to experience alcohol addiction and vice versa. The affinity toward addiction is especially high in the case of posttraumatic stress disorder (PTSD). Animal and human work has suggested that the neurocircuitry largely overlaps in both the expression and extinction of fear and craving. This study involves utilizing one session of non-invasive brain stimulation (repetitive transcranial magnetic stimulation) to enhance extinction learning as measured with functional magnetic resonance imaging, in both healthy individuals and those with PTSD and alcohol addiction. While this is a single session study, the goal of this study is two identify promising new brain targets to be used therapeutically for individuals suffering from PTSD and alcohol addiction.
This study aims to conduct focus groups with adolescents and parents (30 adolescents and 30 parents) to gather feedback to help design an integrated psychological therapy for co-occurring PTSD and substance use among adolescents (Teen COPE). This information will be used to make revisions to the new Teen COPE Therapist Guide and Patient Workbook.
This study will examine the effect of N-Acetylcysteine (NAC), an over-the-counter antioxidant supplement on brains of youth (ages 15-19) using magnetic resonance imaging (MRI). 55 adolescents will receive, in a counterbalanced order, a 10-day course of NAC 1200 mg twice daily and a subsequent 10-day course of matched placebo twice daily, separated by 11 days. Urine samples will be collected at screening and urine and blood samples will be collected before and after each course of medication treatment. Participants will receive a 1- hour MRI scan at baseline and after each treatment trial.
You/your child could be eligible to participate if he or she is:
Between the ages of 15 and 19.
May or may not drink alcohol.
Participants must provide informed consent and youth under 18 must have parental consent to participate.
Compensation is available to those who qualify.
We are currently recruiting women and men ages 18-70 who have had trauma experience and who use alcohol. This research study includes 12 weekly therapy sessions as well as random assignment to receive either the study medication or placebo.
The study will examine the ability of N-acetylcysteine (NAC), an antioxidant/dietary supplement, to reduce the severity of alcohol cravings and withdrawal as well as symptoms associated with PTSD.